Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Study Information
Alliance Study ID: NCCTG-N0539
NCT Study ID (ClinicalTrials.gov): NCT00423917
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Winston Tan, MD, FACP
Status: COMPLETED
Study Description
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Fulvestrant and bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving fulvestrant together with bevacizumab may be an effective treatment for metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving fulvestrant together with bevacizumab works in treating patients with metastatic breast cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information